Anti-GD2 IgG1 monoclonal antibody that targets GD2 on neuroblastoma cells to mediate ADCC and complement-dependent cytotoxicity.
Chimeric IgG1 monoclonal antibody targeting GD2 on tumor cells; flags GD2-positive cells for immune elimination by engaging Fcγ receptor–bearing effectors to mediate antibody-dependent cell-mediated cytotoxicity (and phagocytosis) and activates complement to drive complement-dependent cytotoxicity.
YES
DIRECT
Anti-GD2 IgG1 binds GD2 on target cells and recruits Fcγ receptor–bearing effectors to mediate ADCC/ADCP, and activates complement to induce CDC, killing GD2-positive cells.
Anti-GD2 IgG1 monoclonal antibody that targets GD2 on neuroblastoma cells to mediate ADCC and complement-dependent cytotoxicity.
Chimeric IgG1 monoclonal antibody targeting GD2 on tumor cells; flags GD2-positive cells for immune elimination by engaging Fcγ receptor–bearing effectors to mediate antibody-dependent cell-mediated cytotoxicity (and phagocytosis) and activates complement to drive complement-dependent cytotoxicity.
NO
INDIRECT
Dinutuximab binds GD2 on tumor cells; its Fc engages CD16a (FcγRIIIa) on NK cells/macrophages to mediate ADCC/ADCP and complement lysis of GD2+ cells. CD16a-expressing cells act as effectors, not targets, and are not killed.
Anti-GD2 IgG1 monoclonal antibody that targets GD2 on neuroblastoma cells to mediate ADCC and complement-dependent cytotoxicity.
Chimeric IgG1 monoclonal antibody targeting GD2 on tumor cells; flags GD2-positive cells for immune elimination by engaging Fcγ receptor–bearing effectors to mediate antibody-dependent cell-mediated cytotoxicity (and phagocytosis) and activates complement to drive complement-dependent cytotoxicity.
NO
INDIRECT
Dinutuximab binds GD2 on tumor cells and engages Fcγ receptors (including CD32a) on immune effector cells to mediate ADCC/ADCP and complement-dependent cytotoxicity against GD2+ cells; CD32a+ cells themselves are not targeted or killed.
Anti-GD2 IgG1 monoclonal antibody that targets GD2 on neuroblastoma cells to mediate ADCC and complement-dependent cytotoxicity.
Chimeric IgG1 monoclonal antibody targeting GD2 on tumor cells; flags GD2-positive cells for immune elimination by engaging Fcγ receptor–bearing effectors to mediate antibody-dependent cell-mediated cytotoxicity (and phagocytosis) and activates complement to drive complement-dependent cytotoxicity.
NO
INDIRECT
Dinutuximab binds GD2 on tumor cells and recruits Fcγ receptor–bearing effector cells (including CD64+ cells) to mediate ADCC/ADCP and activates complement (CDC) to kill GD2+ targets; CD64-expressing cells act as effectors, not targets.
Anti-GD2 IgG1 monoclonal antibody that targets GD2 on neuroblastoma cells to mediate ADCC and complement-dependent cytotoxicity.
Chimeric IgG1 monoclonal antibody targeting GD2 on tumor cells; flags GD2-positive cells for immune elimination by engaging Fcγ receptor–bearing effectors to mediate antibody-dependent cell-mediated cytotoxicity (and phagocytosis) and activates complement to drive complement-dependent cytotoxicity.
NO
INDIRECT
Dinutuximab binds GD2 on tumor cells, then engages Fcγ receptor–bearing effectors for ADCC and recruits C1q to activate complement for CDC. C1q-expressing cells are not targeted or killed; complement is an effector in killing GD2-positive cells.